Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
haNK for Infusion · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1, 2x10^9 Cells haNK™ | EXPERIMENTAL | NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous Infusion |
| Name | Type | Description |
|---|---|---|
| haNK™ for Infusion | BIOLOGICAL | haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a). |
Inclusion Criteria: 1. Age ≥ 18 years old. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines. 3. Histologically confirmed, unresectable, locally advanced or metastatic solid malignancy. 4. ECOG performance status of 0 to 2. 5. Have at least...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
haNK for Infusion is an investigational cell-based immunotherapy being studied in solid tumors. It is developed by ImmunityBio, Inc. (ticker IBRX) and has been evaluated in a Phase 1 clinical trial in patients with metastatic or locally advanced solid tumors. It is not an approved therapy and remains in clinical development.
haNK for Infusion has been studied for the treatment of metastatic or locally advanced solid tumors. The Phase 1 trial enrolled adults 18 years and older with these advanced solid tumor types. It is an investigational agent and has not been approved for any indication.
haNK for Infusion is developed by ImmunityBio, Inc., which trades under the ticker IBRX. The company sponsored the Phase 1 study of the agent in patients with metastatic or locally advanced solid tumors in the United States.
haNK for Infusion is in Phase 1 development. It has been evaluated in a single Phase 1 trial, which is now completed, enrolling 6 participants with metastatic or locally advanced solid tumors. It is investigational and has not received FDA approval.
haNK for Infusion has been studied in one clinical trial, NCT03027128, titled QUILT-3.028: Study of haNK for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors. The Phase 1 trial was conducted in the United States, enrolled 6 participants, and is completed.
Yes, haNK for Infusion and haNK refer to the same investigational product. The full name is sometimes written as haNK for Infusion, and the trademarked form haNK™ for Infusion is also used. Both names refer to the ImmunityBio, Inc. (IBRX) agent studied in solid tumors.